×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 6: Pricing & HTA challenges for Cell and Gene Therapies
Session Chair(s)
Alexander Natz, JD
Secretary General
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Session 6: Pricing & HTA challenges for Cell and Gene Therapies
Speaker(s)
Learnings from Launching Kymriah
Etienne Jousseaume
Novartis, Switzerland
Head Market Access Cell and Gene Europe
Learnings from Launching Yescarta
Konstantinos Lykopoulos
Kite Pharma, A Gilead Company, United Kingdom
Senior Director Market Access & Reimbursement
RWE4Access: Payer Initiave for Post-Licensing Evidence for Cell and Gene Therapies
Karen Facey, PhD
University of Edinburgh, United Kingdom
Visiting Senior Research Fellow
Have an account?